Eli Lilly and Company $LLY Stake Decreased by Meadowbrook Wealth Management LLC

Meadowbrook Wealth Management LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 26.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,407 shares of the company’s stock after selling 861 shares during the period. Eli Lilly and Company comprises approximately 3.0% of Meadowbrook Wealth Management LLC’s portfolio, making the stock its 10th largest position. Meadowbrook Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,785,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Coastal Bridge Advisors LLC purchased a new position in shares of Eli Lilly and Company in the second quarter valued at about $2,959,000. Mosaic Family Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares during the period. Moran Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 85.6% during the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock worth $25,072,000 after purchasing an additional 9,638 shares during the period. Generali Investments Management Co LLC grew its stake in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock worth $12,258,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Amundi increased its holdings in Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock valued at $4,649,464,000 after purchasing an additional 454,549 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.6%

LLY traded down $18.95 on Thursday, hitting $1,169.77. The company had a trading volume of 3,090,036 shares, compared to its average volume of 2,974,879. The stock has a fifty day simple moving average of $1,173.51 and a 200-day simple moving average of $1,094.59. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm has a market capitalization of $1.10 trillion, a P/E ratio of 39.25, a P/E/G ratio of 1.42 and a beta of 0.46. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the prior year, the business earned $6.31 EPS. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 36.66 EPS for the current fiscal year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside from recent levels. Benzinga report
• Positive Sentiment: Pipeline diversification remains a key bullish argument. Investors are highlighting next-generation obesity candidate retatrutide, which has shown greater weight loss in trials than Zepbound and could be filed with regulators in 2027. Lilly is also expanding its early-stage Alzheimer’s research and testing obesity drug eloralintide alongside birth control. Eli Lilly obesity business article
• Positive Sentiment: Growth extends beyond GLP-1 drugs. Jaypirca, Inluriyo and Retevmo could support oncology growth, while a new research and licensing agreement with InnoCare covers as many as five drug targets. Commentators argue that Lilly’s manufacturing expansion and broad pipeline create a growth flywheel beyond Mounjaro and Zepbound. Lilly oncology portfolio article
• Neutral Sentiment: Technical support is being watched. A move around the 50-day moving average may signal short-term stabilization, but technical indicators do not resolve the stock’s valuation or fundamental risks. LLY moving average analysis
• Negative Sentiment: Valuation and competition are weighing on sentiment. Lilly trades at a premium multiple, leaving the shares sensitive to pricing pressure, increased competition in obesity medicines and any slowdown in GLP-1 demand. New WHO childhood-obesity guidance may also create uncertainty around how these therapies are used in younger patients. WHO obesity guidance article

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Royal Bank Of Canada upped their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Truist Financial boosted their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners upped their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Berenberg Bank set a $1,400.00 price target on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, September 15th. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,313.43.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last ninety days. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.